Prospective evaluation of the peptide-bound collagen type I cross-links N-telopeptide and C-telopeptide in predicting bone metastases status.

PURPOSE The objective assessment of bone metastases is currently based on serial changes in skeletal survey. We performed a prospective study to determine whether a correlation exists between the biochemical markers of bone turnover and x-ray evaluation of bone metastases in patients with or without bisphosphonate therapy, and whether bone markers are influenced by extraskeletal disease. PATIENTS AND METHODS Patients with either bone or extraskeletal metastases were consecutively enrolled and World Health Organization response criteria were applied for both bone and extraosseous disease every 3 to 4 months. Serum levels of bone-specific alkaline phosphatase (B-AP) and C-telopeptide (ICTP) and urine levels of N-telopeptide (NTX) were measured monthly. The data were analyzed by generalized estimation equation regression. RESULTS We studied 97 patients with bone metastases (52 also with extraskeletal metastases) and 26 with extraosseous disease only. Median time on study was 153 days, and 281 objective evaluations (171 in bone) were performed. With bisphosphonates (49 patients receiving pamidronate and three receiving clodronate), percent change from levels without therapy was 47% for NTX (P <.001) and 69% for B-AP (P =.008). With disease progression in bone, percent change from mean levels during stable disease was 152% for NTX (P <.001) and 144% for ICTP (P <.001) regardless of bisphosphonate therapy. NTX had the highest positive predictive value (71%) for the diagnosis of bone metastases progression. Extraskeletal disease had no significant effect on bone markers. CONCLUSION Urinary NTX may be a valuable bone marker to assess the antiresorptive effect of bisphosphonate therapy and to evaluate the progression of bone metastases.

[1]  L. Demers,et al.  Biochemical markers and skeletal metastases , 2000, Clinical orthopaedics and related research.

[2]  Markku Santala,et al.  Type I and Type III Collagen Metabolites as Predictors of Clinical Outcome in Epithelial Ovarian Cancer , 1999 .

[3]  A. Howell,et al.  Measurement of urinary collagen cross-links indicate response to therapy in patients with breast cancer and bone metastases , 1999, British Journal of Cancer.

[4]  J. Kumazawa,et al.  Use of bone turnover marker, pyridinoline cross‐linked carboxyterminal telopeptide of type I collagen (ICTP), in the assessment and monitoring of bone metastasis in prostate cancer , 1999, The Prostate.

[5]  D. Lacombe,et al.  Assessment of bone response to systemic therapy in an EORTC trial: preliminary experience with the use of collagen cross-link excretion , 1999, British Journal of Cancer.

[6]  G. Hortobagyi,et al.  Markers of bone resorption in patients treated with pamidronate. , 1998, European journal of cancer.

[7]  M. Arning,et al.  Monitoring of multiple myeloma patients by simultaneously measuring marker substances of bone resorption and formation. , 1998, Clinica chimica acta; international journal of clinical chemistry.

[8]  R. Eastell,et al.  Relationships between biochemical and symptomatic response in a double-blind randomised trial of pamidronate for metastatic bone disease. , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  G. Hortobagyi,et al.  Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. , 1996, The New England journal of medicine.

[10]  M. Kovacs,et al.  Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. , 1996, The New England journal of medicine.

[11]  V. Chinchilli,et al.  Biochemical markers of bone turnover in patients with metastatic bone disease. , 1995, Clinical chemistry.

[12]  J A Kanis,et al.  Histomorphometric evidence for osteoclast-mediated bone resorption in metastatic breast cancer. , 1994, Bone.

[13]  P. Virkkunen,et al.  Serum concentration of the cross-linked carboxyterminal telopeptide of type I collagen (ICTP) is a useful prognostic indicator in multiple myeloma. , 1992, British Journal of Cancer.

[14]  R. Rubens,et al.  The clinical course of bone metastases from breast cancer. , 1987, British Journal of Cancer.

[15]  D. Tong,et al.  The palliation of symptomatic osseous metastases final results of the study by the radiation therapy oncology group , 1982, Cancer.

[16]  R. Eastell,et al.  Evaluation of new bone resorption markers in a randomized comparison of pamidronate or clodronate for hypercalcemia of malignancy. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  P. Delmas,et al.  Comparative evaluation of markers of bone resorption in patients with breast cancer-induced osteolysis before and after bisphosphonate therapy. , 1997, British Journal of Cancer.